These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 25877780)

  • 1. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.
    Grosskopf S; Eckert C; Arkona C; Radetzki S; Böhm K; Heinemann U; Wolber G; von Kries JP; Birchmeier W; Rademann J
    ChemMedChem; 2015 May; 10(5):815-26. PubMed ID: 25877780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of 2,5-diaryl-1,3,4-oxadiazole derivatives as novel Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) inhibitors.
    Meng XD; Gao LX; Wang ZJ; Feng B; Zhang C; Satheeshkumar R; Li J; Zhu YL; Zhou YB; Wang WL
    Bioorg Chem; 2021 Nov; 116():105384. PubMed ID: 34601294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of small peptide compounds, molecular docking, and inhibitory activity evaluation against phosphatases PTP1B and SHP2.
    Kostrzewa T; Sahu KK; Gorska-Ponikowska M; Tuszynski JA; Kuban-Jankowska A
    Drug Des Devel Ther; 2018; 12():4139-4147. PubMed ID: 30584278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of Pyrido[1,2-a]pyrimidin-4-one derivatives as novel allosteric SHP2 inhibitors.
    Zhang L; Ma W; Chen Y; Chen Z; Wang F; Xu Y
    Bioorg Chem; 2024 Oct; 151():107661. PubMed ID: 39067422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
    Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
    Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement.
    Mostinski Y; Heynen GJJE; López-Alberca MP; Paul J; Miksche S; Radetzki S; Schaller D; Shanina E; Seyffarth C; Kolomeets Y; Ziebart N; de Schryver J; Oestreich S; Neuenschwander M; Roske Y; Heinemann U; Rademacher C; Volkamer A; von Kries JP; Birchmeier W; Nazaré M
    J Med Chem; 2020 Dec; 63(23):14780-14804. PubMed ID: 33210922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benzo[c][1,2,5]thiadiazole derivatives: A new class of potent Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.
    Wang WL; Chen XY; Gao Y; Gao LX; Sheng L; Zhu J; Xu L; Ding ZZ; Zhang C; Li JY; Li J; Zhou YB
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5154-5157. PubMed ID: 29100798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of demethylincisterol A
    Chen C; Liang F; Chen B; Sun Z; Xue T; Yang R; Luo D
    Eur J Pharmacol; 2017 Jan; 795():124-133. PubMed ID: 27939989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer.
    LaMarche MJ; Acker M; Argintaru A; Bauer D; Boisclair J; Chan H; Chen CH; Chen YN; Chen Z; Deng Z; Dore M; Dunstan D; Fan J; Fekkes P; Firestone B; Fodor M; Garcia-Fortanet J; Fortin PD; Fridrich C; Giraldes J; Glick M; Grunenfelder D; Hao HX; Hentemann M; Ho S; Jouk A; Kang ZB; Karki R; Kato M; Keen N; Koenig R; LaBonte LR; Larrow J; Liu G; Liu S; Majumdar D; Mathieu S; Meyer MJ; Mohseni M; Ntaganda R; Palermo M; Perez L; Pu M; Ramsey T; Reilly J; Sarver P; Sellers WR; Sendzik M; Shultz MD; Slisz J; Slocum K; Smith T; Spence S; Stams T; Straub C; Tamez V; Toure BB; Towler C; Wang P; Wang H; Williams SL; Yang F; Yu B; Zhang JH; Zhu S
    J Med Chem; 2020 Nov; 63(22):13578-13594. PubMed ID: 32910655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of novel triazoloquinazolinone derivatives as SHP2 protein inhibitors.
    Luo R; Wang Z; Luo D; Qin Y; Zhao C; Yang D; Lu T; Zhou Z; Huang Z
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2170-2182. PubMed ID: 34749564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethacrynic acid inhibits STAT3 activity through the modulation of SHP2 and PTP1B tyrosine phosphatases in DU145 prostate carcinoma cells.
    Lee YJ; Song H; Yoon YJ; Park SJ; Kim SY; Cho Han D; Kwon BM
    Biochem Pharmacol; 2020 May; 175():113920. PubMed ID: 32201212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.
    Xie J; Si X; Gu S; Wang M; Shen J; Li H; Shen J; Li D; Fang Y; Liu C; Zhu J
    J Med Chem; 2017 Dec; 60(24):10205-10219. PubMed ID: 29155585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment.
    Ma C; Kang D; Gao P; Zhang W; Wu X; Xu Z; Han H; Zhang L; Cai Y; Wang Y; Wang Y; Long W
    J Med Chem; 2024 Aug; 67(16):13534-13549. PubMed ID: 39110625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of heterocyclic bis-aryl amides as novel Src homology 2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.
    Satheeshkumar R; Zhu R; Feng B; Huang C; Gao Y; Gao LX; Shen C; Hou TJ; Xu L; Li J; Zhu YL; Zhou YB; Wang WL
    Bioorg Med Chem Lett; 2020 Jun; 30(11):127170. PubMed ID: 32273218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of open-chain analogs of cyclic peptides as inhibitors of cellular Shp2 activity.
    Zhen XL; Yin WH; Tian X; Ma ZJ; Fan SM; Han JR; Liu S
    Bioorg Med Chem; 2015 May; 23(10):2562-7. PubMed ID: 25865131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).
    Zhang X; He Y; Liu S; Yu Z; Jiang ZX; Yang Z; Dong Y; Nabinger SC; Wu L; Gunawan AM; Wang L; Chan RJ; Zhang ZY
    J Med Chem; 2010 Mar; 53(6):2482-93. PubMed ID: 20170098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders.
    Yang X; Wang Z; Pei Y; Song N; Xu L; Feng B; Wang H; Luo X; Hu X; Qiu X; Feng H; Yang Y; Zhou Y; Li J; Zhou B
    Eur J Med Chem; 2021 Jun; 218():113341. PubMed ID: 33780898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure based design of selective SHP2 inhibitors by De novo design, synthesis and biological evaluation.
    Liu WS; Jin WY; Zhou L; Lu XH; Li WY; Ma Y; Wang RL
    J Comput Aided Mol Des; 2019 Aug; 33(8):759-774. PubMed ID: 31300938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Synthesis and Antitumor Activity of a Novel Class of SHP2 Allosteric Inhibitors with a Furanyl Amide-Based Scaffold.
    Zhu C; Zhao H; Yang W; Chen K; Liu X; Yu Y; Li R; Tan R; Yu Z
    J Med Chem; 2024 Aug; 67(15):13305-13323. PubMed ID: 39066713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.